Structural Analysis and Molecular Engineering of Oligo-1,6-Glucosidase to Alleviate Product Inhibition
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Researchers engineered oligo-1,6-glucosidase to overcome product inhibition, enhancing its efficiency in glucose production. A triple mutant significantly improved enzyme activity and stability in high glucose concentrations.
Area Of Science
- Biochemistry
- Enzymology
- Structural Biology
Background
- Oligo-1,6-glucosidase is crucial for hydrolyzing α-1,6 glycosidic bonds in isomaltooligosaccharides.
- Product inhibition limits the industrial application of oligo-1,6-glucosidase, particularly in glucose production.
Purpose Of The Study
- To elucidate the structural basis of product inhibition in Paenibacillus sp. STB16 oligo-1,6-glucosidase (pspOGA).
- To engineer pspOGA for reduced product inhibition and improved performance in high glucose environments.
Main Methods
- X-ray crystallography to determine the structure of pspOGA.
- Site-directed mutagenesis (V219A, V219A/K311M/E405A) to engineer the enzyme.
- Enzyme activity assays in high glucose concentrations and glucose mother liquor.
- Circular dichroism and molecular dynamics simulations to elucidate mechanisms.
Main Results
- The crystal structure revealed substrate channel characteristics and the role of Val219 in substrate specificity.
- The triple mutant V219A/K311M/E405A exhibited significantly alleviated product inhibition.
- The triple mutant retained 49.36% activity at 500 mg/mL glucose, compared to 6.25% for V219A.
- The product inhibition constant (Ki) increased 1.3-fold, indicating weakened product binding.
Conclusions
- Rational design targeting specific residues can effectively reduce product inhibition in oligo-1,6-glucosidase.
- Engineered pspOGA demonstrates enhanced industrial applicability for glucose production and byproduct valorization.
- Structural insights provide a foundation for further enzyme optimization.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Competitive inhibitors occupy the active site of enzymes, making them unable to accommodate the substrate. However, sufficiently high...
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...